A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.
Clinical trial NCT07618390 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07618390
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-01
- Primary completion
- 2028-12-01
- Enrollment
- 160
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.